Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2020 / N 4

Безопасное купирование боли у пациента с сердечно-сосудистой патологией
Е.С. Акарачкова, А. Байдаулетова, А.А. Беляев, Д.В. Блинов, Л.Р. Кадырова, Л.В. Климов, О.В. Котова, Д.И. Лебедева, А.С. Орлова, А.М. Ткачев, Е.В. Травникова, О.Н. Яковлев

References

1. Grosser T, Ricciotti E, FitzGerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends in Pharmacological Sciences 2017 Aug;38(8):733-48.
2. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiology and Drug Safety 2014 Jan;23(1):43-50.
3. Akarachkova ES, Kotova OV, Radchenko IA, Travnikova EV. Treatment and rehabilitation of patients with back pain in outpatient settings. Effective Pharmacotherapy 2016;1:32-41 (In Russian).
4. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon ATR, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut 2012 May;61(5):646-64.
5. Hamza AR, Krasniqi AS, Srinivasan PK, Afify M, Bleilevens C, Klinge U, Tolba RH. Gut-liver axis improves with meloxicam treatment after cirrhotic liver resection. World Journal of Gastroenterology 2014 Oct;20(40):14841-54.
6. Lee CY, Tai CJ, Tsai YF, Kuan YH, Lee CH, Huang KH. Prescribing trend of antirheumatic drugs in Taiwan and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. BioMed Research International 2019 Feb;2019:7987529.
7. Foy MC, Vaishnav J, Sperati CJ. Drug-induced hypertension. Endocrinology & Metabolism Clinics of North America 2019 Dec;48(4):859-73.
8. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. British Medical Journal 2011 Jan;342:c7086.
9. Dong YH, Chang CH, Wu LC, Hwang JS, Toh S. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. British Journal of Clinical Pharmacology 2018 May;84(5):1045-56.
10. Hunt RH, Lanas A, Stichtenoth DO, Scarpignato C. Myths and facts in the use of anti-inflammatory drugs. Annals of Medicine 2009;41(6):423-37.
11. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. The American Journal of Medicine 1999 May;106(5B):13S-24S.
12. Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Archives of Internal Medicine 2000 May;160(10):1409-13.
13. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, Sørensen R, Folke F, Buch P, Gadsbøll N, Rasmussen S, Poulsen HE, Køber L, Madsen M, Torp-Pedersen C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archives of Internal Medicine 2009 Jan;169(2):141-9.
14. Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine 2015 Mar;13:55.
15. Bally M, Nadeau L, Brophy JM. Studying additive interaction in a healthcare database: case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction. PLoS One 2018 Aug;13(8):e0201884.
16. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. The Lancet 2003 Aug;362(9382):428-32.
17. Bavry AA, Thomas F, Allison M, Johnson KC, Howard BV, Hlatky M, Manson JAE, Limacher MC. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women’s health initiative. Circulation. Cardiovascular Quality and Outcomes 2014 Jul;7(4):603-10.
18. Dalton SO, Sørensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006;20(2):143-51.
19. Köhler O, Petersen L, Mors O, Gasse C. Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain and Behavior 2015 Aug;5(8):e00338.
20. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in people aged 20–64 years: cohort study using a primary care database. BMC Medicine 2018 Mar;16(1):36.
21. Shin JY, Park MJ, Lee SH, Choi SH, Kim MH, Choi NK, Lee J, Park BJ. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015 Jul;351:h3517.
22. Calvo-Lobo C, Vilar Fernández JM, Becerro-de-Bengoa-Vallejo R, Losa-Iglesias ME, Rodríguez-Sanz D, López PP, López DL. Relationship of depression in participants with nonspecific acute or subacute low back pain and no-pain by age distribution. Journal of Pain Research 2017 Jan;10:129-35.
23. Association of General practitioners (family doctors) of the Russian Federation. Chronic back pain. Clinical guidelines. Moscow, St. Petersburg, Rostov-on-Don, 2014. 20 p. Available from: https://painrussia.ru/publications/reference-materials-and-guides/hbs.pdf Accessed 2020 Dec 25. (In Russian).
24. Karateyev AE. Meloxicam: "golden mean" of nonsteroidal anti-inflammatory drugs. Therapeutic Archive 2014;86(5):99-105 (In Russian).
25. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. The American Journal of Medicine 1999 Dec;107(6A):48S-54S.
26. Maehata Y, Esaki M, Morishita T, Kochi S, Endo S, Shikata K, Kobayashi H, Matsumoto T. Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam. Journal of Gastroenterology 2012 Apr;47(4):387-93.
27. Kagawa T, Kojima S, Shiraishi K, Hirose S, Arase Y, Takashimizu S, Watanabe N, Nagata N, Numata M, Shiozawa H, Nishizaki Y, Toki M, Sugita T, Nomura K, Sakaguchi T, Atsukawa K, Tajima H, Tei Y, Inomoto T, Mine T. Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: a randomized trial. Hepatology Research 2013 Sep;43(9):925-32.
28. Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. The American Journal of Medicine 2004 Jul;117(2):100-6.
29. Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos JM, Klaukka T, Idänpään-Heikkilä JE, Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case–control study from Finland. European Heart Journal 2006 Jul;27(14):1657-63.
30. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety 2013 Jun;22(6):559-70.
31. Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford, England) 2003 Nov;42(11):1342-53.
32. Müller-Schwefe G, Morlion B, Ahlbeck K, Alon E, Coaccioli S, Coluzzi F, Huygen F, Jaksch W, Kalso E, Kocot-Kępska M, Kress H-G, Mangas AC, Margarit Ferri C, Mavrocordatos P, Nicolaou A, Pérez Hernández C, Pergolizzi J, Schäfer M, Sichère P. Treatment for chronic low back pain: the focus should change to multimodal management that reflects the underlying pain mechanisms. Current Medical Research and Opinion 2017 Jul;33(7):1199-210.
33. Van Ryn J, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G, Trummlitz G, Pairet M. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. The Journal of Clinical Pharmacology 2004 Jul;44(7):777-84.
34. Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. European Annals of Allergy and Clinical Immunology 2004 Jun;36(6):215-8.
35. Göksel O, Aydin O, Misirligil Z, Demirel YS, Bavbek S. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. The Journal of Dermatology 2010 Nov;37(11):973-9.
36. Bevis PJ, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. British Journal of Rheumatology 1996 Apr;35(Suppl 1):56-60.
37. Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. American Journal of Kidney Diseases 2005 Mar;45(3):531-9.
38. Winkelmayer WC, Walker SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. The American Journal of Medicine 2008 Dec;121(12):1092-8.
39. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2015 Feb;23(1):1-16.
40. Park HJ, Park MC, Park YB, Lee SK, Lee SW. The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis. Rheumatology International 2014 Jun;34(6):833-40.
41. Belousov YuB, Gurevich KG. General and particular clinical pharmacokinetics. Moscow: Remedium; 2006. 807 p. (In Russian).
42. Wáng YXJ, Wáng JQ, Káplár Z. Increased low back pain prevalence in females than in males after menopause age: evidences based on synthetic literature review. Quantitative Imaging in Medicine and Surgery 2016 Apr;6(2):199-206.
43. Søndergaard E, Willadsen TG, Guassora AD, Vestergaard M, Tomasdottir MO, Borgquist L, Holmberg-Marttila, de Fine Olivarius N, Reventlow S. Problems and challenges in relation to the treatment of patients with multimorbidity: general practitioners’ views and attitudes. Scandinavian Journal of Primary Health Care 2015 Jun;33(2):121-6.
44. Barozzi N, Peeters GG, Tett SE. Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications? BMC Health Services Research 2015 Nov;15:498.

  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]